Аннотация

Ключевые слова

gout women hyperuricemia pharmacotherapy comorbidity.

Полный текст

Скачать статью в PDF

Полная версия статьи в формате PDF

Список литературы

  1. Singh JA, Gaffo A. Gout epidemiology and comorbidities. Semin Arthritis Rheum. 2020;50(3):S11–S16. DOI: 10.1016/j.semarthrit.2020.04.008
  2. Dalbeth N, Bardin T, Doherty M, et al. Discordant American College of Physicians and international Rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN). Nat Rev Rheumatol. 2017;13(9):561–568. DOI: 10.1038/nrrheum.2017.126
  3. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Rheumatol. 2020;72(6):879–895. DOI: 10.1002/art.41247
  4. Tsurko VV, Gromova MA. Gender characteristics of gout course and differences in response to xanthine oxidase inhibitors. Meditsinskiy sovet - Medical council. 2021;(19):164–169. DOI: 10.21518/2079-701X-2021-19-164-169 (In Russ.)
  5. Te Kampe R, Janssen M, van Durme C, et al. Sex differences in the clinical profile among patients with gout: cross-sectional analyses of an observational study. J Rheumatol. 2021;48(2):286–292. DOI: 10.3899/jrheum.200113
  6. Chen-Xu M, Yokose C, Rai SK, et al. Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the National Health and Nutrition Examination Survey, 2007–2016. Arthritis Rheumatol. 2019;71(6):991–999. DOI: 10.1002/art.40807
  7. Major TJ, Topless RK, Dalbeth N, Merriman TR. Evaluation of the diet-wide contribution to serum urate levels: meta-analysis of population-based cohorts. BMJ. 2018;363:k3951. DOI: 10.1136/bmj.k3951
  8. Ignatenko G.A., Mukhin I.V., Prisyazhnyuk M.V., Palamarchuk Yu.S., Panieva N.Yu. Gendernye otlichiya vzaimootnoshenii purinovogo i tireoidnogo obmenov pri podagre [Gender differences in the relationship between purine and thyroid metabolism in gout]. Universitetskaya klinika. 2022;1(42):5–12. (In Russ.)
  9. Narang RK, Topless R, Cadzow M, et al. Interactions between serum urate-associated genetic variants and sex on gout risk: analysis of the UK Biobank. Arthritis Res Ther. 2019;21(1):13. DOI: 10.1186/s13075-018-1787-5
  10. Shostak N.A., Pravdyuk N.G., Loginova T.K., Lazarenko G.N. Giperurikemiya, podagra i komorbidnost’ [Hyperuricemia, gout and comorbidity]. Klinitsist. 2022;16(3):58–64. [https://doi.org/10.17650/1818-8338.2022.16.3.K648](https://doi.org/10.17650/1818-8338.2022.16.3.K648) (In Russ.)
  11. Harrold LR, Etzel CJ, Gibofsky A, et al. Sex differences in gout characteristics: tailoring care for women and men. BMC Musculoskelet Disord. 2017;18(1):108. DOI: 10.1186/s12891-017-1465-9
  12. Sumpter NA, Takei R, Cadzow M, et al. Association of gout polygenic risk score with age at disease onset and tophaceous disease in European and Polynesian men with gout. Arthritis Rheumatol. 2023;75(5):816–825. DOI: 10.1002/art.42393
  13. Lebedev P.A., Garanin A.A., Novichkova N.L. Farmakoterapiya podagry – sovremennye podkhody i perspektivy [Pharmacotherapy of gout – modern approaches and prospects]. Sovremennaya revmatologiya - Modern Rheumatology Journal. 2021;15(4):107–112. DOI: 10.14412/1996-7012-2021-4-107-112 (In Russ.)
  14. Belyaeva I.B., Mazurov V.I., Petrova M.S., Bashkinov R.A. Sovremennaya strategiya lecheniya podagry: fokus na simptom-modifitsiruyushchie i uratsnizhajushchie preparaty [Modern strategy of gout treatment: focus on symptom-modifying and urate-lowering drugs]. Effektivnaya farmakoterapiya - Effective pharmacotherapy. 2024;20(25):44–49. DOI: 10.33978/2307-3586-2024-20-25-44-49 (In Russ.)
  15. Pillinger MH, Mandell BF. Therapeutic approaches in the treatment of gout. Semin Arthritis Rheum. 2020;50(3):S24–S30. DOI: 10.1016/j.semarthrit.2020.04.010
  16. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29–42. DOI: 10.1136/annrheumdis-2016-209707
  17. Panevin T.S., Eliseev M.S., Nasonov E.L. Uratsnizhajushchie preparaty v lechenii podagry: neizvestnoe ob izvestnom [Urate-lowering drugs in gout treatment: the unknown about the known]. Nauchno-prakticheskaya revmatologiya - Rheumatology Science and Practice. 2021;59(6):727–737. (In Russ.)
  18. Perez-Ruiz F, Dalbeth N. Combination urate-lowering therapy in the treatment of gout: what is the evidence? Semin Arthritis Rheum. 2019;48(4):658–668. DOI: 10.1016/j.semarthrit.2018.06.004
  19. Mizuno T, Hayashi T, Hikosaka S, et al. Efficacy and safety of febuxostat in elderly female patients. Clin Interv Aging. 2014;9:1489–1493. DOI: 10.2147/CIA.S70855
  20. Bashkova I.B., Madyanov I.V. Febuksostat kak effektivnyi preparat vybora dlya uratsnizhajushchei terapii pri podagre (klinicheskoe nablyudenie) [Febuxostat as an effective drug of choice for urate-lowering therapy in gout (clinical observation)]. Meditsinskiy sovet - Medical Council. 2022;16(14):137–144. DOI: 10.21518/2079-701X-2022-16-14-137-144 (In Russ.)
  21. Zhang M, Solomon DH, Desai RJ, et al. Assessment of cardiovascular risk in older patients with gout initiating febuxostat versus allopurinol: population-based cohort study. Circulation. 2018;138(11):1116–1126. DOI: 10.1161/CIRCULATIONAHA.118.033992
  22. Mackenzie IS, Ford I, Nuki G, et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet. 2020;396(10264):1745–1757. DOI: 10.1016/S0140-6736(20)32234-0
  23. Garanin A.A., Novichkova N.L., Lebedev P.A. Perspektivy protivovospalitel’noi i uratsnizhajushchei terapii podagry: vektor ot proshlogo k budushchemu [Prospects of anti-inflammatory and urate-lowering therapy for gout: vector from past to future]. Nauchno-prakticheskaya revmatologiya - Rheumatology Science and Practice. 2022;60(2):205–213. (In Russ.)
  24. Pui K, Gow PJ, Dalbeth N. Efficacy and tolerability of probenecid as urate-lowering therapy in gout: clinical experience in high-prevalence population. J Rheumatol. 2013;40(6):872–876. DOI: 10.3899/jrheum.121301
  25. Karageorgiou I, Javed Z, Grooms A, et al. Monitoring and management of uric acid therapy in gout and chronic kidney disease: a single-center retrospective study. Cureus. 2025;17(1):e77813. DOI: 10.7759/cureus.77813
  26. Kunitskaya N.A. Podagra: novye terapevticheskie strategii [Gout: new therapeutic strategies]. Vrach - Physician. 2021;32(6):16–21. DOI: 10.29296/25877305-2021-06-04 (In Russ.)
  27. Chikina M.N., Eliseev M.S., Zhelyabina O.V. Sravnenie effektivnosti i bezopasnosti razlichnykh protivovospalitel’nykh preparatov pri initsiatsii uratsnizhajushchei terapii u patsientov s podagroi (predvaritel’nye dannye) [Comparison of efficacy and safety of various anti-inflammatory drugs during initiation of urate-lowering therapy in gout patients (preliminary data)]. Sovremennaya revmatologiya - Modern Rheumatology Journal. 2021;15(2):50–56. DOI: 10.14412/1996-7012-2021-2-50-56 (In Russ.)
  28. Zhang Y, Neogi T, Chen C, et al. Low-dose aspirin use and recurrent gout attacks. Ann Rheum Dis. 2014;73(2):385–390. DOI: 10.1136/annrheumdis-2012-202589
  29. Navarra S, Rubin BR, Yu Q, et al. Association of baseline disease and patient characteristics with response to etoricoxib and indomethacin for acute gout. Curr Med Res Opin. 2007;23(7):1685–1691. DOI: 10.1185/030079907X210750
  30. Eliseev M.S., Chikina M.N., Zhelyabina O.V. Primenenie kolkhitsina dlya profilaktiki ostrykh pristupov artrita u patsientov s podagroi pri provedenii uratsnizhajushchei terapii (rezultaty pilotnogo issledovaniya) [Use of colchicine for prevention of acute arthritis attacks in gout patients during urate-lowering therapy (pilot study results)]. Sovremennaya revmatologiya - Modern Rheumatology Journal. 2021;15(4):50–55.
  31. Terkeltaub RA, Furst DE, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter randomized double-blind placebo-controlled parallel-group dose-comparison colchicine study. Arthritis Rheum. 2010;62(4):1060–1068. DOI: 10.1002/art.27327
  32. Janssens HJ, Janssen M, van de Lisdonk EH, et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: double-blind randomised equivalence trial. Lancet. 2008;371(9627):1854–1860. DOI: 10.1016/S0140-6736(08)60799-0
  33. Patel AV, Gaffo AL. Managing gout in women: current perspectives. J Inflamm Res. 2022;15:1591–1598. DOI: 10.2147/JIR.S2847
  34. Prozherina Yu., Shirokova I. Podagra: novoe v klinicheskikh rekomendatsiyakh [Gout: new in clinical guidelines]. Remedium. Zhurnal o rossiyskom rynke lekarstv i meditsinskoy tekhnike - Remedium. A magazine about the Russian market of medicines and medical equipment. 2021;2:58–61. (In Russ.)
  35. Sinenko A.A., Mikheeva A.A., Lindeman I.K., Lupach N.M. Opyt primeneniya preparata anakinra u bol’nykh s tyazheloi podagroi, rezistentnoi k traditsionnoi terapii [Experience of using anakinra in patients with severe gout resistant to traditional therapy]. Universum: meditsina i farmakologiya - Universum: Medicine and Pharmacology. 2025;1(6):27–32. (In Russ.)
  36. Chen K, Fields T, Mancuso CA, et al. Anakinra's efficacy is variable in refractory gout: report of ten cases. Semin Arthritis Rheum. 2010;40(3):210–214. DOI: 10.1016/j.semarthrit.2010.03.001
  37. Janssen CA, Oude Voshaar MAH, Vonkeman HE, et al. Anakinra for the treatment of acute gout flares: randomized double-blind placebo-controlled active-comparator non-inferiority trial. Rheumatology (Oxford). 2019;58(8):1344–1352.
  38. Thueringer JT, Doll NK, Gertner E. Anakinra for the treatment of acute severe gout in critically ill patients. Semin Arthritis Rheum. 2015;45(1):81–85. DOI: 10.1016/j.semarthrit.2015.02.006
  39. Liew JW, Gardner GC. Use of anakinra in hospitalized patients with crystal-associated arthritis. J Rheumatol. 2019;46(10):1345–1349. DOI: 10.3899/jrheum.181018